在大B细胞淋巴瘤中，CAR T细胞疗法的疗效不会因先前的双特异性抗体治疗而受损。

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma.

作者信息

Crochet Gilles, Iacoboni Gloria, Couturier Audrey, Bachy Emmanuel, Iraola-Truchuelo Josu, Gastinne Thomas, Cartron Guillaume, Fradon Tom, Lesne Bastien, Kwon Mi, Gounot Romain, Martínez-Cibrian Nuria, Castilla-Llorente Cristina, Abrisqueta Pau, Guerreiro Manuel, Sarkozy Clémentine, Aspa-Cilleruelo Jose María, Camus Vincent, Guidez Stéphanie, Chauchet Adrien, Deconinck Eric, Bouabdallah Krimo, Bosch Francesc, Barba Pere, Morschhauser Franck, Houot Roch

机构信息

Centre Hospitalier Universitaire UCLouvain Namur, Yvoir, Belgium.

Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

出版信息

Blood. 2024 Jul 18;144(3):334-338. doi: 10.1182/blood.2024024526.

DOI:10.1182/blood.2024024526

PMID:38657242

Abstract

In this retrospective study, chimeric antigen receptor T cells remained effective in patients with relapsed/refractory large B-cell lymphoma after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.

摘要

在这项回顾性研究中，嵌合抗原受体T细胞对先前已接触过靶向不同抗原的双特异性抗体（BsAb）的复发/难治性大B细胞淋巴瘤患者仍具有疗效。这些结果与临床实践相关，特别是考虑到BsAb在早期治疗方案中的使用日益增加。